

What is KCC?

A core facility and a resource for researchers, clinicians and industry to facilitate the development of quality assured Advanced Therapy Medicinal Products (ATMPs) and cells for transplantation. To ensure patient safety and benefit, all new ATMPs or cells for transplantation, intended for clinical use, will be evaluated by the priority board at KCC. The production unit Vecura is an integrated part of KCC with expertise in Good Manufacturing Practice (GMP).

The Single Entry Point...

is a support function that guides the client through the required steps from research product to quality assured ATMP for clinical applications, or cells for transplantation.

Vecura GMP facility, provided resources:


Expertise and resources in quality assurance as well as in clean room facility workflows and quality analyses to support and develop customized production processes.

The Pre-GMP facility...

is a facility that will be available for process development before entering full scale GMP. The facility is managed by Karolinska Institutet and collaborates with KCC.

The Priority Board...

evaluates and prioritizes projects within KCC, with focus on patient safety and benefit.



Advanced Therapy Medicinal Products (ATMPs) are Cell Therapy Products, Gene Therapy Products, Tissue Engineered Products or combination products (ATMP + device).




Foto: Medicinsk Bild och Melker Dahlstrand